Financials in USD. Standardized financial statements.
A compact view of how Canntab Therapeutics Limited turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $293,362 | $0 | $133,334 | $240,000 | $26,667 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | -100.0% | -44.4% | +800.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.23M | $263,312 | $0 | $96,385 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | -$939,011 | -$263,312 | $133,334 | $143,614 | $26,667 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | -320.1% | 0.0% | +100.0% | +59.8% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $3.23M | $3.26M | $2.75M | $2.74M | $2.45M | $1.12M | $173,840 | $178,768 | $587,320 | $1.45M |
| Operating Income? | -$4.16M | -$3.52M | -$2.62M | -$2.50M | -$2.42M | -$1.12M | $173,840 | -$178,768 | -$637,705 | -$1.56M |
| EBITDA? | -$2.49M | -$3.13M | -$2.29M | -$2.42M | -$2.37M | -$1.11M | -$173,840 | -$179,004 | -$872,970 | -$1.33M |
| Income Before Tax | -$3.69M | -$4.42M | -$2.61M | -$2.46M | -$2.41M | -$1.12M | -$173,840 | -$178,532 | -$301,241 | -$1.56M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$3.69M | -$4.42M | -$2.61M | -$2.46M | -$2.41M | -$1.12M | -$173,840 | -$178,532 | -$301,241 | -$1.56M |
| EPS? | $-0.10 | $-0.13 | $-0.10 | $-0.10 | $-0.11 | $-0.07 | $-0.75 | $-1.18 | $-1.53 | $-8.30 |
| Diluted EPS? | $-0.10 | $-0.13 | $-0.10 | $-0.10 | $-0.11 | $-0.07 | $-0.75 | $-1.18 | $-1.53 | $-8.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality